Abstract
Purpose: Ibopamine is used when performing provocative tests, thanks to its pharmacological property of increasing ocular pressure in eyes with outflow system impairment. This study summarizes the latest results that we have achieved with reference to its clinical-diagnostic use. Methods: 175 (250 eyes) POAG patients, 101 (190 eyes) glaucoma suspects with mild ocular hypertension, 39 (64 eyes) NTG patients and 163 (326 eyes) healthy volunteers underwent an ibopamine provocative test. Among the POAG and the glaucoma suspects, 49 (92 eyes) and 20 (38 eyes) patients were selected who, starting from the performing of ibopamine test, had at least one year of perimetric follow-up. These patients have been assessed for the perimetric defect progression in relation to the (negative or positive) response to ibopamine. Results: the ibopamine test was positive for 92% of the glaucomatous patients, 61% of the glaucoma suspects, 52% of the NTG patients and 0% of the healthy volunteers. It was observed that 28% of the ibopamine-positive glaucoma suspects showed a perimetric deterioration during an average 2.5-year follow-up. No perimetric deterioration was found on ibopamine-negative glaucoma suspects (Fisher's exact test: p = 0.038). Among glaucomatous patients, 46% of the test-positive individuals showed a progressive trend of the perimetric defect, as against about 8% of glaucomatous test-negative patients (Fisher's exact test: p = 0.003). Conclusions: We believe that the ibopamine provocative test can be usefully applied especially to epidemiological screening studies to identify patients who might develop ocular hypertension or glaucoma and in the follow-up of glaucoma suspects, to identify individuals who have a greater risk of developing perimetric defects.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Virno M, Taverniti L, Taloni M, Ioppolo A, Pellegrino N. Studio sperimentale degli effetti locali e sistemici dell'ibopamina, farmaco dotato di attività adrenergica e dopaminergica, Boll ocul 1986; 65: 1169.
Virno M, Taverniti L, Motolese E, Taloni M, Bruni P, Pecori Giraldi J. Ibopamina: nuovo midriatico non cicloplegico, Boll ocul 1986; 65: 1135.
Virno M, Pecori Giraldi J, Taverniti L, Taloni M, Bruni P. Effetti ipertensivi oculari dell'ibopamina somministrata per via locale in soggetti con turbe idrodinamiche endoculari, Boll ocul 1987; 66: 833.
Virno M, Pecori Giraldi J, Taverniti L, Taloni M, Pannarale L. Intraocular hypertensive effects of topically administered ibopamine in eye with hydrodynamic disorders: a new provocative test for glaucoma. Glaucoma 1990; 12: 88.
Virno M, De Gregorio F, Grechi G, Da Dalt S. Comportamento della pressione oculare e della motilità pupillare dopo somministrazione topica di ibopamina 2% in soggetti sani, jtAtti VI riunione AISG, 1991: 239.
Virno M, Gazzaniga A, Taverniti L, Pecori Giraldi J, De Gregorio F. Dopamine, dopaminergic drugs and ocular hypertension. International Ophthal 1992; 16: 349–53.
Virno M, Pannarale L, Arrico L, De Gregorio F. Increase in aqueous humour production by topical administration of Ibopamine, a dopaminergic agonist, in glaucomatous and healthy eyes. Inv Ophthalm Vis Sci vol 35/4, ARVO meeting abstract issue, 1994: 2052.
Virno M, De Gregorio F, Pannarale L, Taverniti L. Ibopamine, a valuable pharmacological method for diagnosis of glaucoma. Oral presentation at 1st Joint Meeting of American Glaucoma Society and European Glaucoma Society, Reykjavik, Iceland, 1993.
Rolle T, Brogliatti B, Valvo G, Boles Carenini B. Uso dell'ibopamina collirio nell'iter diagnostico del glaucoma ad angolo aperto. Boll Ocul 1991; 70 suppl 1: 247.
Boles Carenini B, Brogliatti B, Boles Carenini A, Valvo G, Sibour G. The ibopamine test in diagnosis of POAG. 1st Joint Meeting of American Glaucoma Society and European Glaucoma Society, Reykjavik July 1993, New trend in Ophthalmology vol IX, 1994; n 2: 75–9.
Nuti A, Ciappetta R, Diadori A, Frezzotti R. Ibopamine provocative test in the diagnosis of hydrodynamic disorders. X international Congress of Eye Research, Stresa 20th-25th september 1992, Exp eye Res 1992; 55 suppl 1: 185.
Lodi M, Novella L, Marras A, Cambiaggi A. Il test all'ibopamina in occhi portatori di sindrome della pseudoesfoliatio. Boll Ocul 1992; suppl 2, vol 50: 111.
Genitti G, Di Staso S, Blasi MA, Balestrazzi A. The effect of N-methyl dopamine 3–4 butyryl ester on eyes with pseudoexfoliation syndrome. Inv Ophth Vis Sci 1995; 36, 4, ARVO meeting abstracts: 3395.
Virno M, Pannarale L, Arrico L, De Gregorio F. Experimental ocular hypertension in rabbit: effects of ibopamine, a dopamine agonist. Inv Ophthalm Vis Sci vol 35/4, ARVO meeting abstract issue, 1995: 3320.
Virno M, De Gregorio F, Sedran L, Taverniti L. Increase in aqueous humor production following D1 receptors activation by means of Ibopamine. Oral Presentation at Congress of European Glaucoma Society, Paris, June 1996.
Virno M, Pecori Giraldi J, Pellegrino N, Ioppolo A. Correlation between vascular activity and permeability in the oculat hypotensive mechanism of action of adrenergic drugs. Glaucoma 1980; 2: 280.
Virno M, Pecori Giraldi J, Pellegrino N, Taverniti L, De Gregorio F, Sedran L. Farmaci attivi sull'emodinamica oculare. Boll Ocul 1993; 72, suppl 2: 51.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
De Gregorio, F., Giraldi, J.P., Pannarale, L. et al. Ibopamine in glaucoma diagnostics: a new pharmacological provocative test. Int Ophthalmol 20, 151–155 (1996). https://doi.org/10.1007/BF00212962
Issue Date:
DOI: https://doi.org/10.1007/BF00212962